Clinical Trial Update: Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant [Phase 2]

View source ↗

Summary

A Phase 2 trial from Columbia University evaluating rifaximin to prevent recurrent HCV-related liver fibrosis after liver transplant; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Liver Fibrosis

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Columbia University | Conditions: Hepatitis C | Phase 2 | Status: UNKNOWN